CBD Dosage Guide: Finding Your Perfect Dose in 2026

Few aspects of CBD generate more confusion — and more frustration — than dosage. Unlike conventional medications, where a specific dose is determined by clinical trials and printed on the label, CBD products come in dozens of concentrations and formats, and effective doses vary by individual, condition, and delivery method. This is not a flaw unique to CBD — many nutraceuticals and even some pharmaceuticals have highly variable individual dose requirements — but the CBD market's historical lack of regulation has meant that accurate dosage guidance has often been absent or dangerously vague.

The variability in optimal CBD dose across individuals reflects genuine biological differences: in ECS receptor density and function, in FAAH enzyme activity, in CYP450 metabolic rate, in body composition, and in the severity and type of the condition being addressed. A 60 kg person with mild anxiety may achieve excellent results at 20 mg/day, while a 90 kg person with chronic fibromyalgia may require 150 mg/day. Both responses are perfectly normal. The key is a systematic approach — start low, go slow, measure, and adjust.

Body weight is a useful starting heuristic for CBD dosing, analogous to how paediatric drug doses are calculated. The commonly referenced starting point in integrative medicine is 0.5 mg of CBD per kilogram of body weight per day for mild effects, with 1–2 mg/kg/day for moderate-to-significant conditions. Use the following reference table as your starting framework:

• 50 kg (110 lb): Starting dose 25 mg/day; therapeutic range 25–100 mg/day
• 60 kg (132 lb): Starting dose 30 mg/day; therapeutic range 30–120 mg/day
• 70 kg (154 lb): Starting dose 35 mg/day; therapeutic range 35–140 mg/day
• 80 kg (176 lb): Starting dose 40 mg/day; therapeutic range 40–160 mg/day
• 90 kg (198 lb): Starting dose 45 mg/day; therapeutic range 45–180 mg/day
• 100 kg (220 lb): Starting dose 50 mg/day; therapeutic range 50–200 mg/day

These are starting points, not fixed prescriptions. Individuals with conditions known to require higher therapeutic concentrations (fibromyalgia, refractory pain, severe anxiety) should expect to reach the upper end of their weight-based range. Always titrate upward gradually rather than jumping straight to high doses — this allows your ECS to adapt and helps identify your personal minimum effective dose, which may be substantially lower than the upper limit.

Bioavailability refers to the proportion of a dose that reaches systemic circulation in an active form. For CBD, this varies enormously by delivery method and is the single most important factor in understanding why the same labelled dose on two different products can produce very different effects. Understanding bioavailability allows you to make meaningful comparisons across formats and to calculate true effective doses.

• Sublingual oil: 20–35% bioavailability. Fastest onset (15–45 min), moderate duration (4–6 hours). Best for flexible, responsive dosing.
• Oral capsules/gummies: 6–19% bioavailability (significantly improved by taking with fatty food — up to 4-5x higher absorption in one study). Slowest onset (1–2 hours), longest duration (6–8 hours). Best for sustained daily maintenance.
• Inhaled (vaporised flower or concentrate): 31–56% bioavailability — the highest of any consumer format. Fastest onset (seconds to minutes), shortest duration (2–3 hours). Best for acute symptom management.
• Topical (creams, balms): Systemic bioavailability near zero; local tissue bioavailability meaningful for superficial targets. Best for localised joint and muscle pain.
• Water-soluble/nanoemulsion CBD: Emerging technology with claimed bioavailability improvements of 2–5x over standard oil; some products have peer-reviewed validation. Best for high-dose requirements.

The practical implication: if you are taking 50 mg of CBD in capsule form (effective dose ~6–9 mg), you may need to take 75–100 mg in a capsule to achieve an effect equivalent to 25 mg sublingually. When switching between formats, adjust your dose based on bioavailability rather than maintaining the same labelled number. This is why people who switch from sublingual to capsules often report reduced effectiveness — they have not adjusted for the lower bioavailability.

Titration is the process of starting at a low dose and incrementally increasing it over time until the desired therapeutic effect is achieved or dose-limiting side effects emerge. It is standard practice in pain medicine, psychiatry, and neurology for many medications, and it is the approach universally recommended by experienced CBD clinicians. The slower the titration, the more precisely you can identify your minimum effective dose — and the lower your dose, the lower your cost, your risk of side effects, and your risk of drug interactions.

A practical CBD titration protocol: Week 1 — take your body-weight-based starting dose once daily (sublingually, 60–90 minutes before bed if sleep is a goal, or morning if anxiety management is the aim). Record subjective effect on a 1–10 scale daily. Week 2–3 — if no meaningful effect, add a second equal dose in the morning. Week 4 onward — increase total daily dose by approximately 10–15 mg per week until you achieve your target effect or identify a plateau. Give each dose increment at least 5–7 days before increasing again — the ECS adapts gradually and immediate judgements after a single dose are unreliable.

A minority of users describe a paradoxical worsening — increased anxiety, mild nausea, or sleep disruption — when they escalate beyond a certain dose. If this occurs, reduce by one increment and hold that dose for two weeks. This is consistent with the inverted U-shaped dose-response demonstrated in Zuardi's anxiety research and reflects individual variation in ECS responsiveness. Your optimal dose may genuinely be lower than you expect.

One of the most persistent sources of consumer confusion in the CBD market is the disconnect between how products are labelled and how the dose is actually calculated. A bottle might state "500 mg CBD" on the front, but that tells you the total content of the bottle — not the dose per serving. To calculate the dose per drop (for a tincture), use this formula: Total CBD (mg) ÷ Bottle volume (ml) ÷ 20 (drops per ml) = CBD per drop (mg).

For a 10ml bottle containing 1000 mg of CBD: 1000 ÷ 10 ÷ 20 = 5 mg per drop. For a 10 mg daily starting dose, you would take 2 drops. For a 30 mg dose, you would take 6 drops. Some brands label by percentage instead of total milligrams: a 5% CBD oil in a 10ml bottle contains 500 mg total (5% of 10,000 mg = 500 mg). Always perform this calculation when comparing products across brands — a "high strength" 1000 mg product in a 30ml bottle (3.3% CBD, ~1.67 mg/drop) may deliver less per drop than a "standard" 500 mg product in a 10ml bottle (5% CBD, 2.5 mg/drop).

While individual titration always takes precedence over general guidelines, the clinical literature provides useful reference ranges by condition that can help set appropriate expectations:

• General wellness / daily supplement: 10–30 mg/day. This range is supported by the ECS supplementation hypothesis — maintaining endocannabinoid tone rather than achieving pharmacological effects.
• Anxiety (GAD, social anxiety): 25–100 mg/day for daily management; 100–300 mg for acute situational anxiety. Shannon 2019 used 25–75 mg; Zuardi 2011 SPST study used 600 mg in a single acute dose.
• Sleep: 25–80 mg taken 30–60 minutes before bed. Shannon 2019 baseline was 25 mg; many practitioners use 40–80 mg for sleep-predominant presentations.
• Chronic pain (inflammatory, neuropathic): 50–150 mg/day in split doses. Some fibromyalgia and severe neuropathic pain cases may require up to 300 mg/day under guidance.
• Epilepsy (Epidiolex protocol): Up to 20 mg/kg/day — far exceeding consumer supplement ranges and only appropriate under specialist supervision with pharmaceutical-grade CBD.
• Skincare / acne: Topical application of 3–15 mg per application area, not systemic dosing.

Systematic tracking transforms CBD use from guesswork into a data-driven process. The most effective approach is to use validated psychometric scales relevant to your primary goal, measured at the same time each week. For anxiety: the GAD-7 (Generalised Anxiety Disorder 7-item scale) — freely available online, takes 2 minutes, and is the same tool UK GPs use. For sleep: the Pittsburgh Sleep Quality Index (PSQI) or the ISI (Insomnia Severity Index), both validated and freely accessible. For pain: the Brief Pain Inventory or a simple 0–10 numerical rating scale assessed morning and evening.

Supplement your formal measures with a daily journal noting: the dose and format taken, the time taken, any other relevant variables (alcohol, caffeine, exercise, stress events), and a brief subjective rating. This diary serves two functions: it reveals patterns (does CBD work better on days with good sleep? less effective after alcohol?) and it provides a narrative record you can share with your GP if you choose to involve them in your CBD use. Wearable devices (Fitbit, Oura Ring, Apple Watch) can add objective sleep data to your subjective assessments, which is particularly valuable for sleep applications.

Several signals suggest your CBD dose needs adjustment. Signs your dose is too low: no perceptible change after 3–4 weeks of consistent use, symptoms unchanged by tracking measures, no variation in symptom severity on days you forget to take CBD versus days you do. If these apply, proceed with titration upward according to the protocol above.

Signs your dose is too high: increased anxiety or restlessness (particularly at doses above 150 mg/day — the inverted U-shape effect), excessive sedation during the day, GI discomfort (loose stools, reduced appetite), and — importantly — worsening of the symptoms you were trying to address. High-dose CBD's CYP450 interactions also become more significant above ~100 mg/day; if you are on any regular medication and have noticed changes in its effects after increasing your CBD dose, this is a signal to reduce and speak with your doctor.

Finally, if you have been on a stable dose for several months and notice gradually reducing effectiveness — often described as the CBD "not working as well as it used to" — consider a scheduled break of 1–2 weeks. While CBD does not produce tolerance in the classical pharmacological sense (CB receptor downregulation as with THC), subtle changes in ECS receptor sensitivity over prolonged use have been suggested. A brief break often restores full responsiveness to your previously effective dose.